PT  - JOURNAL ARTICLE
AU  - Creemers, J.H.A.
AU  - van der Doelen, M.J.
AU  - van Wilpe, S.
AU  - Hermsen, R.
AU  - Duiveman-de Boer, T.
AU  - Somford, D.M.
AU  - Janssen, M.J.R.
AU  - Sedelaar, J.P.M.
AU  - Mehra, N.
AU  - Textor, J.
AU  - Westdorp, H.
TI  - Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer
AID  - 10.1101/2020.11.11.20229831
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.11.20229831
4099  - http://medrxiv.org/content/early/2020/11/12/2020.11.11.20229831.short
4100  - http://medrxiv.org/content/early/2020/11/12/2020.11.11.20229831.full
AB  - Purpose Radium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute to the OS advantage. We performed a comprehensive evaluation of the immunological changes in mCRPC patients by phenotyping the peripheral blood mononuclear cells (PBMCs) during radium-223 therapy.Experimental Design In this prospective, single-arm, exploratory study, PBMCs of 30 mCRPC patients were collected before, during, and after treatment with radium-223. Lymphocyte and monocyte counts were analyzed to get insight into general immune cell trends. Next, we analyzed changes in T cell subsets, myeloid-derived suppressor cells (MDSCs), and immune checkpoint expression using linear regression models. Per subset, the 6-month change (% of baseline) was determined. Bootstrapped 95% confidence intervals were used to measure the degree of uncertainty of our findings.Results We observed a substantial decrease in absolute lymphocyte counts (−0.12 * 10^9 cells/L per injection, 95% CI: -0.143 - -0.102). Simultaneously, an increase was observed in the proportion of T cells that expressed costimulatory (ICOS) or inhibitory (TIM-3, PD-L1, and PD-1) checkpoint molecules. Moreover, the fraction of two immunosuppressive subsets – the regulatory T cells and the monocytic MDSCs – increased throughout treatment. These findings were not more pronounced in patients with an ALP response during therapy.Conclusion Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.Competing Interest StatementM.J. van der Doelen received research grants form Bayer (to institution) during the conduct of the study, travel expenses from Bayer, research grants from Janssen Pharmaceuticals, and personal fees from Astellas outside the submitted work. R. Hermsen is member of the advisory board of Bayer and received personal fees and travel expenses from Bayer outside the submitted work. D.M. Somford is a member of the advisory boards of Janssen Pharmaceuticals, Astellas and Bayer and received research grants from Astellas outside the submitted work. N. Mehra is a member of the advisory boards of Bayer, Bristol Myers Squibb, Roche, Merck Sharp and Dome, Astellas and Janssen Pharmaceuticals, and reports personal fees from Bayer, research grants and personal fees from Janssen Pharmaceuticals, research grants and personal fees from Merck Sharp and Dohme, research grants and personal fees from Roche, research grants and personal fees from Astellas, research grants and personal fees from AstraZeneca, research grants and personal fees from Sanofi, research grants from Pfizer an research grants from Genzyme outside the submitted work. No potential conflicts of interest were disclosed by the other authors.Funding StatementThis research was partly funded by Bayer The Netherlands. The funding organization had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, and preparation, review, or approval of the abstract or the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of the Radboudumc (Nijmegen, The Netherlands) and Canisius-Wilhelmina hospital (Nijmegen, The Netherlands).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code is available on GitHub. https://github.com/jeroencreemers/Immunophenotyping-radium223-mCRPC